NOTICE: VA Offer of Exclusive Patent License to UTECH Products Inc. DBA Endosoft LLC.

**BY THE:** Department of Veterans Affairs, Office of Research and Development (VA)

**ON:** Dec 21, 2021

**SUMMARY:** Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to UTECH Products Inc. DBA Endosoft LLC, 135 Broadway, Schenectady, NY 12350 an exclusive license to U.S. Patent Application No. 63/036,280 and PCT/US2021/036420, associated with VA Invention Disclosure number 2020-150 titled, "Methods and Systems for Determining an Object Map".

**TECH NAME:** "Artificial Intelligence-Augmented Visualization with Real Time Histology Mapping of Colorectal Polyps"

**ACTION:** Intent

**DATES:** Comments must be received on or before Jan 6, 2022.

**ADDRESS:** Send comments to Mr. Kip Bodi, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (617) 390-4728 (this is not a toll-free number), Email: kip.bodi@va.gov

**FOR FURTHER INFORMATION CONTACT:** Send comments to Mr. Kip Bodi, Technology Transfer Specialist, Office of Research and Development (14RDTT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (617) 390-4728 (this is not a toll-free number), Email: kip.bodi@va.gov

**SUPPLEMENTARY INFORMATION:** The Federal Government's patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as UTECH Products Inc. DBA Endosoft LLC has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.